Preskoči na sadržaj
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Sva polja
Naslov
Autor
Tema
Signatura
ISBN/ISSN
Oznaka
Pronađi
Napredno
Efficacy and safety of MPC-786...
Citiraj ovo
Pošalji tekstualnu poruku
Pošalji ovo e-mailom
Ispiši
Izvezi zapis
Izvezi u RefWorks
Izvezi u EndNoteWeb
Izvezi u EndNote
Stalna poveznica
Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study
Bibliografski detalji
Glavni autori:
Black, S
,
Wilcock, G
,
Haworth, J
,
Hendrix, S
,
Zavitz, K
,
Christensen, D
,
Binger, M
,
Bass, S
,
Laughlin, M
,
Swabb, E
Format:
Conference item
Izdano:
2006
Primjerci
Opis
Slični predmeti
Prikaz za djelatnike knjižnice
Slični predmeti
Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.
od: Laughlin, M, i dr.
Izdano: (2006)
Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
od: Wilcock, G, i dr.
Izdano: (2005)
Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
od: Black, S, i dr.
Izdano: (2008)
Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
od: Wilcock, G, i dr.
Izdano: (2007)
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
od: Wilcock, G, i dr.
Izdano: (2008)